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Abstract
The androgen receptor (AR) is a ligand-activated transcription factor of the male and female
reproductive tracts whose activity is modulated by coregulator binding. We recently identified
melanoma antigen gene protein-11 (MAGE-11) of the MAGEA gene family that functions as an AR
coregulator by binding the AR N-terminal FXXLF motif. Here we report that MAGE-11 is expressed
in a temporal fashion in endometrium of normally cycling women. Highest levels of MAGE-11
mRNA and protein occur in the mid-secretory stage, coincident with the window of uterine
receptivity to embryo implantation. Studies in human endometrial cell lines together with the
hormone profile of the menstrual cycle and pattern of estrogen receptor-α expression in cycling
endometrium suggest the rise in MAGE-11 mRNA results from down-regulation by estradiol during
the proliferative phase and up-regulation by cyclic AMP signaling in the early and mid-secretory
stage. In agreement with its coregulatory function, MAGE-11 localizes with AR in glandular
epithelial cell nuclei in the mid-secretory stage. The increase in AR protein in the mid-secretory
endometrium without an increase in AR mRNA suggests MAGE-11 stabilizes AR in glandular
epithelial cell nuclei. This was supported by expression studies at low androgen levels indicating AR
stabilization by MAGE-11 dependent on the AR N-terminal transactivation domain. The results
suggest that MAGE-11 functions as a coregulator that increases AR transcriptional activity during
the establishment of uterine receptivity in the human female.
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The requirement for androgen receptor (AR) mediated gene regulation in male sex
development is demonstrated by individuals with the androgen insensitivity syndrome. In this
X chromosome-linked disorder, 46XY genetic males with single missense mutations in the
AR gene are born with ambiguous or completely female external genitalia. However, identical
loss-of-function mutations have relatively little phenotypic effect in 46XX carrier females
(Quigley et al., 1995) due in part to the double allele status of the AR gene and to random and
partial inactivation of the X chromosome. Female mice homozygous for AR inactivating
mutations have reproductive abnormalities that implicate a role for AR in fertility (Shiina et
al., 2006). Reduced fertility in homozygous female AR knockout mice is associated with
prolonged estrous cycles, fewer oocytes after super-ovulation, follicular atresia and diminished
endometrial growth (Hu et al., 2004). The AR knockout mouse demonstrates that AR plays an
important role in normal female reproductive physiology, but the mechanisms underlying these
functions remain poorly understood.
Understanding the mechanisms of transcriptional regulation by AR is an area of active
investigation. AR transcriptional activity depends on two critical domains, activation function
1 (AF1) in the N-terminal region and activation function 2 (AF2) in the ligand-binding domain.
Both AF1 and AF2 serve as interaction sites for coregulator proteins that bridge to the
transcriptional machinery (Heinlein and Chang, 2002). One AR coregulator identified recently
is the X chromosome-linked melanoma antigen gene protein-11 (MAGE-11 or MAGEA-11)
of the MAGEA gene family. MAGE-11 was identified as an AR inter-acting protein in a yeast
two-hybrid screen of a human testis library using the AR N-terminal FXXLF motif as bait (Bai
et al., 2005). MAGE-11 is one of the so-called cancer-testis antigens and is expressed in
primates, but not in rats, mice or other mammals. MAGE-11 binds the AR FXXLF motif and
increases androgen-dependent AR transcriptional activity (Bai et al., 2005). Binding of
MAGE-11 to the AR FXXLF motif inhibits the androgen-dependent AR N- and C-terminal (N/
C) interaction between the AR FXXLF motif and AF2. Transcriptional activity derived from
AF2 is established by competitive binding by AF2 of the AR FXXLF motif, SRC/p160
coactivator LXXLL motifs and FXXLF motifs in putative AR coregulators (He et al., 2002;
Hsu et al., 2003).
Our studies on MAGE-11 in human endometrium arose from observations that AR is required
for female reproductive function (Shiina et al., 2006) and that MAGE-11 is expressed in tissues
and cell lines of the human female reproductive tract in a manner that correlates with AR
expression (Bai et al., 2005). Based on its ability to increase AR transcriptional activity through
increased AR stabilization and SRC/p160 coactivator recruitment, we considered whether
MAGE-11 provides an androgen signal amplification mechanism in the human female. In this
report, we show that MAGE-11 is expressed in a temporal fashion in human endometrium
during the menstrual cycle. Highest levels of MAGE-11 mRNA and protein coincide with the
window of uterine receptivity to embryo implantation. MAGE-11 expression is regulated in
human endometrial cell lines by steroids and second messengers consistent with the
endometrial expression and hormone profile in the menstrual cycle.
Materials and Methods
Antibodies
MAGE-11 protein expression was determined using antibodies raised in rabbits against human
MAGE-11 N-terminal
peptides 94ITQIFPTVRPADLTR108, 59DLPRVQVFREQANLEDRSPRR79
and 13SPASIKRKKKREDS26 (Pocono Rabbit Farm & Laboratory, Inc., Canadensis, PA).
Each peptide is specific to MAGE-11 and is coded by a separate 5′ exon (Bai et al., 2005).
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MAGE-11 anti-bodies were purified by peptide affinity chromatography using antigen-
coupled Affi-Gel 10 (Bio-Rad) (Bai et al., 2005). Antigens were coupled in 0.2 M
ethanolamine, pH 8.0, and antibodies were eluted in 0.1 M glycine, pH 3.0, neutralized with
0.1 volume of 1 M Tris–HCl, pH 8.0 (He et al., 2002) and amended to 0.05 M NaCl and 5%
glycerol. Antibody specificity was verified by preadsorption and immunoblot analysis of
human MAGE-11 (pSG5-MAGE-11) expressed in COS cells which migrates on SDS
polyacrylamide gels as 67±3 kDa.
Endometrial tissue sampling
Endometrial biopsies were obtained under approved IRB protocols with informed consent at
different stages of the menstrual cycle from 21 healthy cycling women volunteers 18–35 years
of age with 25–35 day intermenstrual intervals. Women were excluded who used hormone
contraception or medications that alter reproductive hormone levels or had infertility or upper
reproductive tract disease. Cycle day was determined by the first day of menstruation. Urinary
LH was determined by a home test kit (Ovuquick One Step, Conception Technologies, San
Diego, CA). Endometrial biopsies were obtained from proliferative, early, middle and late
secretory stages and excluded for evidence of inflammation, hyperplasia or neoplasia. Study
participants were randomized for endometrial sampling on a specific predetermined day after
the onset of menstruation for proliferative phase samples, and a specific day after the urinary
LH surge for post-ovulatory samples. Endometrium samples were classified by patient reported
cycle day and number of days after the LH surge. Histological staging of hematoxylin and
eosin stained fixed sections according to Noyes et al. (1950, 1975) served to confirm cycle
stage, but no changes were made to cycle day or phase based on histological criteria. Samples
for immunostaining were placed in 10% neutral buffered formalin in the clinic within 10 min
of surgical removal. Samples for RNA extraction were flash frozen and stored at −80°C.
Immunostaining
Paraffin embedded serial sections (8 µm) of normal human endometrium were immunostained
using deparaffinized fixed sections treated with 83% methanol and 5% H2O2 at room
temperature to reduce endogenous peroxidase activity. Tissue sections were not treated further
for rabbit polyclonal MAGE-11 antibody MagAb94–108 (9 µg/ml) and progesterone receptor
(PR) H-190 anti-body (Santa Cruz sc-7208, 2 µg/ml). For MAGE-11 antibodies MagAb59–
79 (4 µg/ml) and MagAb13–26 (4 µg/ml), sections were further treated with 0.05 mg/ml trypsin
for 5 min at room temperature followed by washing in cold phosphate-buffered saline (PBS).
For preadsorption studies, antibodies were pre-incubated with 0.1 or 0.2 mg/ml respective
peptide antigens for 2 days at 4°C, centrifuged for 10 min at 4°C at 12 600g and used under
identical conditions as untreated antibody. For rabbit polyclonal AR antibody (Abcam ab3510,
0.38 µg/ml) and mouse monoclonal human estrogen receptor α(ERα) antibody (NovoCastra
NCL-ER-6F11, 1:500 dilution), tissue sections were exposed to 0.01 M sodium citrate, pH 6.0
for 15 min in a microwave at high setting (Balaton et al., 1993). Sections were blocked with
2% normal goat serum, incubated overnight at 4°C in a humidified chamber with primary
antibody, and blocked with 2% normal goat serum followed by a 1 h incubation at room
temperature with biotinylated secondary antibody (Vector Labs). Slides were incubated with
avidin DH-biotinylated horse-radish peroxidase H complex (Vectastain Standard ABC kit,
Vector Labs) for 1 h at room temperature followed by immersion in 3,3′-diaminobenzidine
tetrahydrochloride (Aldrich Chemical Co.) at 150 mg/200 ml 0.05 MTris–HCl buffer
containing 0.002% hydrogen peroxide for 10 min with constant stirring. Sections were exposed
to osmium vapors and counterstained with 0.05% toluidine blue in 30% ethanol, dehydrated,
cleared in xylene and mounted with Permount (Fisher). Photographs were taken using a
SPOT-4 Megapixel Digital Camera (Diagnostic Instruments, Inc., Sterling Heights, MI)
attached to a Nikon ECLIPSE E600 microscope and prepared using SPOT image processing
software.
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RNA extraction, first-strand cDNA synthesis and quantitative real-time RT–PCR
Total RNA was extracted from frozen endometrial biopsies using RNAqueous-4 PCR kit
(Ambion) and from endometrial-epithelial cell line 1 (ECC-1) and Ishikawa cells using RNeasy
Plus Mini Kit (Qiagen). First strand cDNA was synthesized using SuperScript II reverse
transcriptase (Invitrogen). For human endometrium biopsies, real-time PCR was performed on
a Stratagene Mx3000 (Stratagene, La Jolla, CA) using Taqman chemistry and the delta delta
Ct relative quantitation method using peptidylprolyl isomerase A (PPIA, cyclophilin A) as a
constitutive housekeeping control gene. PPIA expression was constant in endometrial biopsies
taken across the menstrual cycle (S.L.Y., unpublished observations). Samples were analyzed
in triplicate and the efficiency of the primer probe sets confirmed for each run using serial
dilutions of a standardized sample. For ECC-1 and Ishikawa cell lines, real-time PCR was
performed on a Lightcycler using LightCycler TaqMan Master mix (Roche) in a final reaction
volume of 20 µl.
PCR primers and fluorogenic probes included Hs99999904-m1 (PPIA), Hs00377815-m1
(MAGE-11), Hs00907244-m1 (AR) and Hs174860-m1 (ERα) from Assays-On-Demand
(Applied Biosystems, Foster City, CA). PPIA primers amplify a 98 bp 317–414 nucleotide (nt)
fragment coding for amino acid residues 102–133 in exon 4 (GenBank Y00052). MAGE-11
primers amplify a 63 bp 123–185 nt DNA fragment coding for amino acid residues 24–43 with
the probe centered at 154 nt (Genbank AY747607.1) (Bai et al., 2005) overlapping the exon
2 and 3 junction. AR primers amplify a 99 bp 2197–2295 nt DNA fragment coding for AR
amino acid residues 612–644 with the probe centered at 2244 nt (Lubahn et al., 1988)
overlapping the exon 3 and 4 junction. ERα primers amplify a 62 bp 1093–1154 nt DNA
fragment corresponding to amino acid residues 245–264 at assay location 1124 nt (GenBank
NM-000125) spanning the exon 3 and 4 boundary. β-glucuronidase (GusB) forward primer 5′-
tggtgctgaggattggca-3′ and reverse primer 5′-tagcgtgtcgaccccattc-3′ amplify a 65 bp region
coding for amino acid residues 120–140 and the probe 5′-tgcccattcctatgccatcgtgtg-3′ overlaps
the exon 2 and 3 boundary.
PCR reactions (20 µl) contained cDNA from 0.4 µg total RNA, 4 µl Light- Cycler TaqMan
Master mix (Roche) and 0.5 µl 20 × TaqMan Mix (Applied Biosystems) for AR and MAGE-11,
and 0.5 µM primer and 0.2 µM probe for GusB. Thermal cycler conditions were one cycle at
95°C for 10 min followed by 55 cycles of 95°C for 15 s, 60°C for 25 s and 72°C for 1 s. A
nontemplate RNase-free water control was included in each run. Four serial 10-fold dilutions
of cDNA or plasmid DNA were amplified in duplicate to construct standard curves for each
gene using LightCycler software. Sample mRNA levels were extrapolated based on standard
curves and Ct values and normalized to GusB, which except for dihydrotestosterone (DHT),
was constant under the test conditions and expressed as ratios of target gene to GusB. GusB is
constitutively expressed without significant variation due to hormonal stimulation in multiple
endometrial cell lines including ECC-1 and Ishikawa (S.L.Y., unpublished observations).
Immunoblot analysis
MAGE-11, ERα and PR protein levels in ECC-1 (2 × 106/6 cm dish) and Ishikawa cells (4 ×
106/10 cm dish) were determined by immunoblot. Cells were plated in medium without phenol
red containing 5% charcoal stripped serum after culturing in the same media for 4 days. Cells
were treated, washed and harvested in cold PBS containing 1 mM dithiothreitol, 1 mM
phenylmethylsulfonyl fluoride, 5 µg/ml leupeptin, 5 µg/ml pepstatin A and 5 µg/ml aprotinin,
and solubilized in buffer containing 1% Triton X-100, 0.15 M NaCl, 0.5 mM EDTA, 1%
sodium deoxycholate, 0.1% SDS, 50 mM Tris–HCl, pH 7.4 and protease inhibitors listed
above. AR and MAGE-11 protein interactions were performed in COS cells (1.8 × 106 cells/
10 cm dish) transfected using DEAE dextran with 2 µg wild-type or mutant pCMVhAR and
5 µg pCMV-FLAG-MAGE-11. Cells were washed, harvested in cold PBS and solubilized as
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above. Protein concentration was determined by BioRad assay using bovine serum albumin as
standard. Extracts were separated on 10% acrylamide gels containing SDS and probed with
MagAb94–108 immunoglobulin G (8µg/ml at 4°C), rabbit polyclonal AR32 (1 µg/ml), PR
H-190 (Santa Cruz Biotechnology, 1:500 dilution), mouse monoclonal human ERα antibody
(NovoCastra NCL-ER-6F11, 1:150 dilution) and mouse monoclonal β-actin antibody (Abcam,
1:5000). COS cell expression of pSG5-MAGE-11, pSG5-PR-B, pSG5-PR-A and
pCMVhERα served as positive controls.
Transcription assays
Human endometrial Ishikawa cells were maintained in Eagle’s minimum essential medium
supplemented with 10% fetal bovine serum, penicillin, streptomycin and 2 mM L-glutamine.
Human endometrial ECC-1 cells were maintained in RPMI 1640 medium containing 10% fetal
bovine serum, penicillin, streptomycin and 2 mM L-glutamine. ECC-1 and Ishikawa cells (7.5
× 104/ well of 12-well plates) were transfected using FuGENE-6 (Roche Applied Science) as
described (Askew et al., 2007) with 0.1 µg PSA-Enh-Luc reporter vector, 2 ng pCMVhAR,
pCMVhAR-FXXAA or 25 ng pCMVhAR1-660 and 50–250 ng pSG5-MAGE-11. After 24 h,
cells were placed in serum-free medium with and without 1 nM DHT and assayed the next day
for luciferase activity using a Lumistar Galaxy (BMG Labtech) multiwell plate luminometer.
Results
Menstrual cycle dependence of MAGE-11 protein in human endometrium
Timing of MAGE-11 expression relative to several steroid receptors was determined in serial
sections of endometrial biopsies from normally cycling women at different stages of the
menstrual cycle using MAGE-11 antibodies raised against three MAGE-11 N-terminal
peptides and antibodies to AR, PR and ERα. We found similar MAGE-11 immunostaining in
endometrial sections for each MAGE-11 anti-peptide antibody and loss of immunoreactivity
after preadsorbing with the respective peptide immunogens (data not shown). The survey of
MAGE-11 expression in endometrial sections was performed using MAGE-11 antibody
MagAb94–108.
The majority of proliferative stage endometrial specimens lacked prominent immunostaining
for MAGE-11 in the small symmetrical glands that characterize this stage, with some
immunoreactivity evident in stromal cell nuclei (Fig. 1A). Immunostaining for AR and PR was
similarly weak in glandular epithelial nuclei throughout the proliferative stage, and more
prominent in stromal cell nuclei (Fig. 1B and C). In contrast, ERα immunostaining was intense
in glandular epithelial and stromal cell nuclei throughout the proliferative phase (Fig. 1D).
Early secretory stage endometrium is characterized by elongating glands with prominent
subnuclear vacuoles (Noyes et al., 1950, 1975; Murray et al., 2004). Immunostaining for
MAGE-11 increased in glandular epithelial and stromal cell nuclei in the early secretory stage
LH+5 and paralleled increased immunostaining for AR (Fig. 1E and F). PR was evident in the
early secretory stage but ERα immunostaining declined (Fig. 1G and H). MAGE-11 and AR
persisted in the mid-secretory stage LH+9, and ERα and PR were heterogeneous between the
glands (Fig. 1I–L). By the late secretory stage LH+14 (cycle day 24), MAGE-11, AR, PR and
ERα immunostaining declined (Fig. 1M–P).
The results suggest a parallel increase in MAGE-11 and AR during the early and mid-secretory
endometrial glandular epithelium when ERα levels declined.
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MAGE-11 mRNA expression in normal cycling human endometrium
Timing of MAGE-11 mRNA expression in the cycling endometrium was investigated by
quantitative real-time PCR using RNA extracted from frozen biopsies obtained at different
stages of the cycle. MAGE-11 mRNA levels measured in individual samples were low during
the proliferative phase between menstrual cycle Days 5 and 10 (Fig. 2A). MAGE-11 mRNA
levels increased after LH+1, were elevated between LH+5 and LH+10, and declined at LH
+11. There was a 30–70-fold increase in MAGE-11 mRNA during the early and mid-secretory
phase relative to the proliferative and late secretory stages (Fig. 2B). Timing of maximal
MAGE-11 mRNA expression coincided with the window of receptivity to embryo implantation
between LH+6 and LH+10 (Fig. 2E).
In contrast, AR mRNA levels were higher in individual biopsy samples from the proliferative
and late secretory endometrium, and lower in the early and mid-secretory phase (Fig. 2C).
However, these differences were not significant when patients were grouped (Fig. 2D) by the
classical cycle stage shown in Fig. 2E. PR mRNA levels were relatively constant through the
cycling endometrium (data not shown) and ERα mRNA declined during the early and mid-
secretory stage as summarized in Fig. 3. The relative levels of MAGE-11 mRNA exceeded
AR and ERα mRNA by 10–100-fold in the early and mid-secretory phase, whereas AR mRNA
exceeded MAGE-11 mRNA by 2–20-fold in the proliferative and late secretory stages (Fig.
3). In untreated ECC-1 and Ishikawa human endometrial cell lines, AR exceeded MAGE-11
mRNA by 50–100-fold (~100 MAGE-11 mRNA copies/µg total RNA, data not shown)
indicative of the proliferative or late secretory endometrial cell stage.
The data suggest a reciprocal relationship between AR and MAGE-11 mRNA expression in
human endometrium through the menstrual cycle, with increased MAGE-11 mRNA expression
coincident with the window of receptivity to embryo implantation. The greater AR and
MAGE-11 immunostaining during the early to mid-secretory stage raised the possibility that
MAGE-11 stabilizes AR in the secretory endometrium.
Hormone regulation of MAGE-11
We investigated the hormone regulation of MAGE-11 in ECC-1 and Ishikawa human
endometrial cell lines that express AR, ERα and PR (Tabibzadeh et al., 1990; Nishida et al.,
1996; Lovely et al., 2000; Hanifi-Moghaddam et al., 2005; Mo et al., 2006). MAGE-11 mRNA
levels increased in ECC-1 cells during 72 h of culture in phenol red-free, charcoal stripped
serum medium in the absence of added hormone (Fig. 4A). The increase in MAGE-11 mRNA
was blocked by 10 nM estradiol (E2) in a dose-dependent manner, with partial inhibition by
0.01 nM E2 (Fig. 4A and B). The inhibitory effect of E2 required >6 h (data not shown) and
was ERα mediated since the ICI-182780 antagonist increased MAGE-11 mRNA levels in the
absence and presence of E2 (Fig. 4B). The increase in MAGE-11 mRNA over time in cultures
containing charcoal stripped serum appeared to result from depletion of estrogenic activity.
This was supported by a ~7-fold increase in MAGE-11 mRNA in ECC-1 cells cultured in
serum-free medium (data not shown). In contrast, AR mRNA levels increased ~3-fold in
ECC-1 cells in response to 10 nM E2 (Fig. 4C). The increase in AR mRNA was detected at 1
nM E2 and was blocked by ICI-182780 (Fig. 4D).
MAGE-11 mRNA levels increased 8–12-fold in ECC-1 cells in response to 2 mM dibutyryl-
cyclic AMP (cAMP) (Fig. 5A) and ~4-fold by 50 µM forskolin, but were unchanged for up to
48 h after treatment with 100 units/ml human chorionic gonadotropin, 10 nM progesterone, 10
nM DHT or 10 ng/ml epidermal growth factor (EGF) (data not shown). The lack of response
to progesterone was not due to absence of PR since pretreatment of ECC-1 cells with 10 nM
E2 for 48 h increased PR-B levels as shown in Fig. 6A below, yet MAGE-11 mRNA was not
increased by progesterone with or without pretreatment with E2 (data not shown). The cAMP
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induced increase in MAGE-11 mRNA in ECC-1 cells was inhibited by 10 nM E2 (Fig. 5B).
AR mRNA levels decreased transiently between 0.5 and 6 h in ECC-1 cells in response to
dibutyryl-cAMP (Fig. 5C) but were otherwise stable over 72 h (Fig. 5D).
Similar induction of MAGE-11 mRNA by dibutyryl-cAMP was seen in Ishikawa cells (Fig.
7). As in ECC-1 cells (data not shown),MAGE-11 mRNA levels increased in a dose-dependent
manner in response to dibutyryl-cAMP (Fig. 7A), but the cAMP-dependent increase in
MAGE-11 mRNA was inhibited to a lesser extent by 10 nM E2 in Ishikawa cells (Fig. 7A)
than in ECC-1 cells (Fig. 5B). This may reflect lower ERα levels in Ishikawa cells compared
with ECC-1 cells as shown in Fig. 6B below. The increase in AR mRNA by 10 nM E2 was
inhibited by dibutyryl-cAMP in Ishikawa cells (Fig. 7B).
Hormone dependent changes in MAGE-11 protein were more difficult to assess. The level of
the ~67 kDa MAGE-11 protein was lower in Ishikawa cells than in ECC-1 cells (Fig. 6C) and
MAGE-11 protein levels declined in Ishikawa cells in response to 10 nM E2 (Fig. 6D).
However, an increase in MAGE-11 protein by cAMP was not detected within the 48-h culture
period (data not shown).
The data indicate cAMP-dependent up-regulation and E2-dependent down-regulation of
MAGE-11 expression in the ECC-1 and Ishikawa endometrial cell lines. E2 had opposing
effects on AR and MAGE-11 by increasing AR mRNA and reducing MAGE-11 mRNA.
MAGE-11 increases AR transcriptional activity and stability
Expression studies were performed to determine the effect of MAGE-11 on AR transactivation
in the endometrial-epithelial cell lines. Transient expression of MAGE-11 increased the
androgen-dependent transcriptional activity of full-length AR in ECC-1 and Ishikawa cells
(Fig. 8A and B) and the constitutive activity of AR1-660, an AR N-terminal and DNA binding
domain fragment (shown for Ishikawa cells, Fig. 8C). The MAGE-11-dependent increase in
AR transcriptional activity in Ishikawa cells was reduced by the AR FXXAA mutation (Fig.
8B), providing further evidence that the AR N-terminal FXXLF motif is the primary interaction
site for MAGE-11. Androgen independent AR activation increased slightly with the expression
of MAGE-11 in Ishikawa cells (Fig. 8B) as observed in other cell lines (Bai et al., 2005). The
results support the coregulatory function of MAGE-11 in endometrial cells and suggest that
MAGE-11 increases AR transcriptional activity dependent on the AR N-terminal FXXLF motif
and transactivation domain.
We found that MAGE-11 can stabilize AR through mechanisms that require the AR N-terminal
AF1 transactivation domain (amino acid residues 142–337) in a manner that complements the
stabilizing effects of the AR N/C interaction in the presence of DHT. At a saturating DHT
concentration (10 nM), AR was stabilized in an AR FXXLF (23FQNLF27) motif manner (Fig.
9A and B, lanes 1–6), which reflects the effects of the AR N/C interaction (Kemppainen et
al., 1992; Langley et al., 1995; He et al., 2000). AR stabilization by MAGE-11 in the absence
or at low levels of DHT (Fig. 9B, lanes 1 and 2) was also largely dependent on the FXXLF
motif (lanes 4 and 5), with less of an increase in the AR-FXXAA mutant by MAGE-11 (Fig.
9B, lane 4). The AR stabilizing effect of MAGE-11 required, in addition, the AR N-terminal
AF1 transactivation domain, but was not strictly linked to AR transcriptional potential.
Transcriptionally inactive AR nuclear transport mutant AR-4KM (lanes 10–12) and DNA
binding mutant AR-C576A (lanes 13–15) were stabilized by the AR N/C interaction in the
presence of DHT, and by MAGE-11 in the absence and presence of DHT. However,
transcriptionally inactive ARΔAF1, which deletes N-terminal residues 142–337, was stabilized
by the N/C interaction, but only weakly by MAGE-11 (lanes 7–9). At 10 nM DHT, AR levels
increased as a result of the N/C interaction, and MAGE-11 protein levels declined depending
on the transcriptional status of AR. MAGE-11 levels declined in the presence of DHT-bound
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wild-type AR (Fig. 9, lanes 1–3) but not with transcriptionally inactive mutant ARΔAF1 (lanes
7–9), nuclear transport mutant AR-4KM (lanes 10–12) or the DNA binding mutant AR-C576A
(lanes 13–15).
The results suggest that the AR N-terminal AF1 transactivation domain is required for AR
stabilization by MAGE-11 and that MAGE-11 may increase AR transcriptional activity in the
relatively low circulating androgen environment of the early and mid-secretory endometrium
by stabilizing AR.
Discussion
MAGE-11 belongs to a 12 member MAGEA gene family encoded on a 3.5 Mb segment at
Xq28 of the human X chromosome (Rogner et al., 1995). Before its identification as an AR
coregulator, the function of MAGE-11 was unknown. Androgen binding to AR initiates a
sequence of events that involves AR stabilization by the N/C interaction (Kemppainen et al.,
1992; Langley et al., 1995; He et al., 2000) and AR interaction with coregulatory proteins (He
et al., 2001; Bai et al., 2005). MAGE-11 selectively activates AR by binding the AR N-terminal
FXXLF motif sequence 23FQNLF27 (Bai et al., 2005). By binding the AR FXXLF motif,
MAGE-11 competitively inhibits the AR N/C interaction, because the same AR FXXLF motif
that binds MAGE-11 also binds AF2 in the AR ligand-binding domain in the presence of bound
androgen. Binding of MAGE-11 therefore interrupts the AR N/C interaction and increases
coactivator recruitment by AF2. Thus, one mechanism for increased AR transcriptional activity
by MAGE-11 is increased AR recruitment of the SRC/ p160 coactivators SRC1, TIF2 and
AIB1 (SRC3) (Bai et al., 2005). These coactivators, along with p300 and pCAF, are expressed
in human endometrium during the menstrual cycle and are known to increase AR
transcriptional activity (Mertens et al., 2001; Gregory et al., 2002).
In the present report, we demonstrate that MAGE-11 is expressed in a temporal fashion in
nuclei of the endometrial glandular epithelium of normally cycling woman. Highest levels of
MAGE-11 mRNA and protein occur between LH+5 through LH+10 of the menstrual cycle
and coincide with the window of receptivity at LH+6 through LH+10 (Psychoyos, 1973;
Lessey, 2000). Localization of MAGE-11 with AR in epithelial cell nuclei suggests that AR
and MAGE-11 have a transcriptional role in preparing the uterus for implantation and
pregnancy.
The original report of Noyes et al. (1950, 1975) provided a histological classification scheme
for the developing human endometrium during the secretory (luteal) phase. Histological
landmarks included epithelial mitoses, nuclear pseudostratification and subnuclear vacuoles.
The staging scheme of Noyes et al. placed subnuclear vacuoles between LH+2 and LH+4. In
agreement with a recent report of normally cycling women (Murray et al., 2004), we observed
persistence of subnuclear vacuoles into endometrial stage LH+5 and LH+6 and later into the
mid-secretory phase. With these latter criteria, the temporal alignment between MAGE-11
mRNA expression and the window of receptivity to embryo implantation suggest that
MAGE-11 may serve as a new biomarker for human endometrial staging.
Our studies in human endometrial cell lines demonstrate MAGE-11 expression is inhibited by
estrogen. The importance of ERα-mediated down-regulation of genes in establishing the timing
of receptivity to implantation (Lessey et al., 1988) is supported by studies on αvβ3, a proposed
marker of receptivity whose expression is inhibited by E2 (Somkuti et al., 1997). We observed
a surprising time-dependent increase in MAGE-11 mRNA in endometrial cell cultures in
phenol red-free, charcoal stripped serum, an increase that was blocked by E2. The increase in
MAGE-11 mRNA was more evident in ECC-1 than Ishikawa cells and appeared to reflect a
time-dependent depletion of estrogenic activity from phenol red-free, charcoal stripped serum
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containing medium. The concept that basal culture conditions exert an estrogenic effect on
MAGE-11 expression was supported by the increase in MAGE-11 mRNA expression after
treatment with the ERα antagonist, ICI-182780. Differences in sensitivity to E2 inhibition of
MAGE-11 expression between the endometrial cell lines correlated with ERα levels even
though estrogen increased AR mRNA levels in both cell lines. In agreement with these findings,
the concentration of E2 required to inhibit MAGE-11 expression was ~100-fold less than the
concentration required to increase AR expression. There may also be differences in
autonomous second messenger signaling between the endometrial cell lines because cAMP
reversed the inhibitory effect of E2 to a greater extent in Ishikawa cells than in ECC-1 cells.
Timing of the post-ovulatory increase in MAGE-11 mRNA and protein in endometrial biopsies
and the increase in MAGE-11 mRNA in response to dibutyryl-cAMP in endometrial cell lines
raise the possibility that LH secreted by the pituitary acts on the endometrium to increase
MAGE-11. Indeed, studies suggest direct effects of LH on the uterus, independent of the ovary,
that help to prepare the endometrium for implantation (Tesarik et al., 2003). Progesterone also
acts directly on endometrial epithelial cells to increase gene expression during the secretory
phase and indirectly through stromal cells by increasing expression of paracrine factors
(Lessey, 2003) such as calcitonin, a proposed marker of uterine receptivity that increases cAMP
production in Ishikawa cells (Li et al., 2006). The effects of cAMP are enhanced by
progesterone in stromal cells (Tang et al., 1993) and activin A is a component of the cAMP
signaling pathway (Tierney and Giudice, 2004). Differentiation of human endometrial stromal
cells is promoted by prostaglandin-E2, LH and relaxin (Telgmann et al., 1997), each of which
increases adenylate cyclase activity and cAMP levels during the transition from proliferative
to secretory stage in the human endometrium (Bergamini et al., 1985; Tanaka et al., 1993).
The delay in maximal MAGE-11 mRNA and protein expression until 5 days after the LH surge
during the mid-luteal estrogen surge might be explained by the decline in ERα that occurs in
the early to mid-secretory phase. Mid-luteal depletion of ERα would abrogate E2-induced
suppression of MAGE-11 mRNA, allowing MAGE-11 levels to increase. ERα is down-
regulated by progesterone in epithelial cells, suggesting that increasing progesterone during
the mid-secretory phase suppresses ERα at a time when MAGE-11 increases and uterine
receptivity is established (Fazleabas et al., 1999; Lessey et al., 2006). MAGE-11 expression
appears to be coordinately regulated by the menstrual cycle dependent timing of hormone and
receptor levels through the combined actions of cAMP, E2 and progesterone and the mid-luteal
decline in ERα. Changing levels of MAGE-11 provides a mechanism to modulate AR
transcriptional activity during endometrial maturation. Additional studies are needed to
establish the mechanisms whereby AR and MAGE-11 influence endometrial receptivity and
whether alterations in MAGE-11 expression have a role in polycystic ovarian syndrome and
endometriosis.
Compared with the established roles for ERα and PR as transcriptional regulators in the cyclic
function of the human endometrium (Lessey et al., 1988), relatively little is known about AR.
The endometrium is influenced by androgens that are reported to circulate near constant low
levels during the menstrual cycle (Jabbour et al., 2006). Evidence that AR signaling is required
for embryo implantation derives from fertility defects in female AR knockout mice (Hu et
al., 2004). In agreement with previous studies in the primate endometrium during the menstrual
cycle (Fujimoto et al., 1994; Adesanya et al., 1999; Slayden et al., 2001; Apparao et al.,
2002; Slayden and Brenner, 2004), we found that AR mRNA levels are up-regulated by
estrogen in the human endometrial cell lines and only transiently reduced by cAMP. AR levels
were reported higher in endometrial stromal cells compared with glandular epithelial cells
during the proliferative phase, were persistent in stromal cells in the mid-secretory stage (LH
+7 to LH+10), and present at lower levels in luminal and glandular epithelial cells late in the
cycle (Lessey et al., 1988; Horie et al., 1992; Mertens et al., 1996, 2001; Slayden et al.,
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2001; Apparao et al., 2002; Burton et al., 2003; Narvekar et al., 2004; Villavicencio et al.,
2006). The opposing actions of cAMP and E2 on AR and MAGE-11 appear to provide a closely
linked regulatory mechanism for controlling AR transcriptional activity in the cycling
endometrium. The actions of these signaling molecules occur within a context of inhibitory
progesterone effects on estrogen and androgen signaling and the influence of growth factors
and hormones in a dynamic inter-relationship between the stroma and epithelium (Lessey,
2003; Jabbour et al., 2006).
We presented evidence that MAGE-11 increases AR levels in the absence and at low levels of
androgen contingent on the AR N-terminal AF1 transcriptional activation domain (residues
142–337) that lies outside the 23FQNLF27 AR FXXLF interaction site for MAGE-11. AR
stabilization by MAGE-11 is also supported by the FXXLF motif and MAGE-11-dependent
increase in AR half-life in the absence of androgen (Bai et al., 2005). The loss of ARΔAF1
stabilization by MAGE-11 was not linked to its lack of androgen-dependent transcriptional
activity because other transcriptionally inactive AR mutants were stabilized by MAGE-11.
Rather, it appears that the AF1 region is part of an extended AR N-terminal interaction region
for MAGE-11. The inability of the AR-FXXAA mutant to completely eliminate the AR-
dependent transcriptional effects of MAGE-11 provides further evidence that regions outside
of the FXXLF motif contribute to the AR interaction with MAGE-11. Alternatively, there may
be an AF1 interacting protein that facilitates AR stabilization by MAGE-11 in the absence or
at low levels of androgen.
The menstrual cycle dependent expression of MAGE-11 could modulate AR levels and account
for the increase in AR immunostaining during the early and mid-secretory endometrium when
circulating androgen levels are low. The timing of MAGE-11 expression in the mid-secretory
endometrium in response to hormone signals of the menstrual cycle may enhance AR
transcriptional activity during the window of uterine receptivity to embryo implantation.
However, the mechanisms whereby MAGE-11 controls AR transcriptional activity are only
beginning to be fully understood. Recent studies have shown that EGF increases site-specific
phosphorylation and ubiquitinylation of MAGE-11 which modulates the interaction between
AR and MAGE-11 (Bai and Wilson, 2008). EGF signaling may be an additional important
control mechanism relevant to the human endometrium that modulates the AR and MAGE-11
interaction. Additional studies are needed in biopsies, endometrial cell lines and primary cell
cultures, to establish the androgen-dependent transcriptional events important for developing
and maintaining the window of receptivity to embryo implantation.
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Figure 1. Menstrual cycle stage dependence of MAGE-11, AR, PR and ERα immunostaining in
human endometrium
Paraffin-fixed sections of normal human endometrium were immunostained as described in
the section Materials and Methods using antibodies against MAGE-11 (MagAb94–108, 9 µg/
ml, A, E, I andM), AR (Abcam ab3510, 0.38 µg/ml, B, F, J and N), PR (Santa Cruz H-190, 2
µg/ml, C, G, K and O) and ERα (NovoCastra NCL-ER-6F11, 1:500 dilution, D, H, L and
P). Representative sections are shown for proliferative (patient N003, cycle day 9 (CD 9), A–
D), early secretory LH+5 (patient M135, CD 15, E–H), mid-secretory LH+9 (patient M122,
CD 27, I–L) and late secretory LH+14 (patient M087, CD 24, M–P). Brown reaction product
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represents positive immune reactivity against toluidine blue counterstain. Original
magnification 60X
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Figure 2. MAGE-11 and AR mRNA levels in normal human endometrial biopsies through the
menstrual cycle
(A) Relative MAGE-11 mRNA levels in individual subjects by menstrual cycle day (CD) or
day following the LH surge were assayed using total RNA from frozen human endometrium
samples of normal cycling women. cDNA was prepared and amplified by real-time PCR as
described in Materials and Methods. Normalized values are shown relative to LH+14. (B) Log
scale plot of average relative MAGE-11 mRNA levels by menstrual cycle stage assayed as
described in the section Materials and Methods and expressed as mean ± SD for proliferative
phase (CD 1–14) and early (LH+1 to LH+5), mid (LH+6 to LH+10) and late secretory stage
(LH+11 to LH+14). (C) Relative endometrial AR mRNA levels in individual subjects by
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menstrual CD or days following the LH surge. Normalized values of AR mRNA are shown
relative to LH+14. (D) Log scale plot of average relative AR mRNA levels by menstrual cycle
stage assayed as described in the section Materials and Methods and (B) above. (E) Schematic
of hormone profiles for LH (magenta), 17β-E2 (cyan), progesterone (green), and MAGE-11
mRNA levels (black dotted line) based on the 28 day human menstrual cycle relative to the
window of endometrial receptivity to embryo implantation at LH+6 through LH+10 (orange
box), CD and day following the LH surge. Proliferative stage is CD 1–13, LH surge at CD 14,
ovulation at LH+1, early secretory LH+1 to LH+5 (CD 15–19), mid-secretory LH+6 to LH
+10 (CD 20–24) and late secretory LH+11 to LH+14 (CD 25–28)
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Figure 3. Linear plot of stage-dependent changes in MAGE-11, AR and ERα mRNA in normal
human endometrium through the menstrual cycle
MAGE-11 (black), AR (gray) and ERα mRNA (white) were assayed as described in the section
Materials and Methods. Relative mean mRNA levels in different stages of the cycle were not
indicative of absolute levels but illustrate greater AR than MAGE-11 mRNA levels in the
proliferative and late secretory phase and greater MAGE-11 than AR mRNA in the early and
mid-secretory stages
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Figure 4. Estrogen regulation of MAGE-11 and AR mRNA in ECC-1 cells
ECC-1 cells were cultured and plated in phenol red free, 5% charcoal stripped serum medium
and the next day harvested (0 time) or the medium replaced with or without 10 nM E2 and
harvested 24, 48 and 72 h later (A and C). Dose response studies were performed at increasing
E2 concentrations or 1 µM ICI-182780 with and without 0.1 nM E2 as indicated and harvested
48 h later (B and D). Shown are relative levels of MAGE-11 (A and B) and AR (C and D)
mRNA determined from total RNA by real-time PCR as described in the section Materials and
Methods from duplicates of two 10 cm dish cultures extrapolated from standard curves and
threshold cycle Ct values and expressed as ratios of target gene to control gene β-glucuronidase
(GusB) ± SD
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Figure 5. cAMP regulation of MAGE-11 and AR mRNA in ECC1 cells
ECC-1 cells were cultured, plated and treated in phenol red free, 5% charcoal stripped serum
medium with and without 2 mM dibutyryl-cAMP (A and D), 2 mM dibutyryl-cAMP with and
without 10 nM E2 (B) and 0.5 mM dibutyryl-cAMP (C) for the times indicated. Extracted RNA
was analyzed as described in the section Materials and Methods. Shown are relative levels of
MAGE-11 (A and B) and AR (C and D) mRNA from duplicates of two 10 cm dish cultures
extrapolated from standard curves and threshold cycle Ct values expressed as ratios of target
gene to control gene β-glucuronidase (GusB) ± SD
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Figure 6. Immunoblots of PR, ERα and MAGE-11 in ECC-1 and Ishikawa cells
(A) For PR, ECC-1 (lanes 2 and 3) and Ishikawa cells (lanes 4 and 5) were treated with and
without 10 nM E2 for 48 h as indicated and protein (50 µg/lane) probed using PR H-190
antibody (Santa Cruz Biotechnology, 1:500 dilution). Human PR-B and PR-A were expressed
together in COS cells from pSG5hPR-B and pSG5hPR-A and analyzed by immunoblot as
controls (lane 1, 2 µg total protein). Protein extracts were separated on 10% acrylamide gels
containing SDS calibrated using Kaleidoscope prestained molecular weight markers (BioRad)
indicated on the left. (B) For ERα, ECC-1 (lanes 2 and 3) and Ishikawa cells (lanes 4 and 5)
were treated with and without 10 nM E2 for 24 h as indicated and protein (80 µg/lane) probed
using a mouse monoclonal human ERα antibody (NovoCastra NCL-ER-6F11, 1:150 dilution).
Human ERα was expressed in COS cells from pCMVhERα and included on the immunoblot
(lane 1, 1 µg total protein) as a control. (C) ECC-1 (lane 2) and Ishikawa cells (lane 3) were
untreated and protein extracts (50 µg/lane) were probed on immunoblots using MagAb94–108
immunoglobulin G (8 µg/ml). Human MAGE-11 was expressed in COS cells from pSG5-
MAGE-11 and included on the immunoblot as a control (lane 1, 0.5 µg total protein). (D)
Ishikawa cells were treated with and without 10 nM E2 for 48 h as indicated and protein (50
µg/lane) probed with MagAb94–108 immunoglobulin G (8 µg/ml). Expression of pSG5-
MAGE-11 was included as a positive control (lane 1)
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Figure 7. Estrogen and cAMP regulation of MAGE-11 and AR mRNA in Ishikawa cells
Ishikawa cells were cultured, plated and treated in phenol red free, 5% charcoal stripped serum
medium with and without 0.1, 0.4 and 2 mM dibutyryl-cAMP and/or 10 nM E2 for 48 h. RNA
was analyzed as described in the section Materials and Methods. Shown are relative MAGE-11
(A) and AR (B) mRNA levels from duplicates of two 10 cm dish cultures extrapolated from
standard curves and threshold cycle Ct values expressed as ratios of target gene to control gene
β-glucuronidase (GusB) ± SD
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Figure 8. Increase in AR transcriptional activity by MAGE-11 in endometrial cells
ECC-1 (A) and Ishikawa cells (B) were transfected in 12-well plates with 0.1 µg PSA-Enh-
Luc, 2 ng pCMVhAR or pCMVhAR-FXXAA (23FQNAA27) with and without 100 ng pSG5-
MAGE-11 per well using FuGENE 6 as described in the section Materials and Methods. In
(C), Ishikawa cells were transfected with 25 ng pCMV5 empty vector (p5) or pCMVhAR1-660
(coding for the AR N-terminal and DNA binding domains) with and without 50, 100 or 250
ng pSG5-MAGE-11 as indicated. Luciferase activity expressed as average ± SEM. is
representative of three independent experiments
Bai et al. Page 23













Figure 9. Modulation of AR and MAGE-11 protein levels
(A) Schematic of full-length human AR amino acid residues 1–919 including AR FXXLF
motif 23FQNLF27, AF1 N-terminal activation domain, DNA binding domain (DBD), nuclear
localization signal (NLS), ligand binding domain (LBD) and AF2. (B) Immunoblots of protein
extracted from COS cells transfected with 2 µg wild-type pCMVhAR (WT) or pCMVhAR
mutants AR-FXXAA with 23FQNLF27 changed to FQNAA (He et al., 2000), ARΔAF1 with
the Δ142–337 deletion (Zhou et al., 1995), nuclear transport mutant 4KM with R617M,
K618M, K632M and K633M mutations (Zhou et al., 1994) and DNA binding mutant C576A
(Zhou et al., 1995) in the absence (upper panel) and presence (lower 2 panels) of 5 µg pCMV-
Flag-MAGE-11. Cells were incubated for 24 h in 10% charcoalstripped serum medium in the
absence and presence of 2 and 10 nM DHT as indicated. Cells were extracted as described in
the section Materials and Methods and total protein (10 µg/lane) separated in 10% acrylamide
gels containing SDS. AR was detected using AR32 rabbit polyclonal antibody (1:100, upper
two panels) and Flag-MAGE-11 with anti-Flag M2 mouse monoclonal antibody (Sigma,
1:2000, lower panel). The lower portion of the blot was probed with a mouse monoclonal β-
actin antibody as a loading control
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